Structure Therapeutics (GPCR) Proxy filing summary

Executive summary

• Annual general meeting scheduled for June 17, 2026, to be held virtually, with shareholders voting on director elections, auditor ratification, and executive compensation.

• Shareholders of record as of April 20, 2026, are eligible to vote; voting can be done online, by phone, or by mail.

• Forward-looking statements address executive compensation plans and product development milestones, with risks highlighted in annual and periodic reports.

Voting matters and shareholder proposals

• Three Class III directors are nominated for election to serve until 2029.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay) is included.

• Shareholder proposals for the 2027 meeting must be submitted by December 24, 2026, for proxy inclusion.

Board of directors and corporate governance

• Board consists of seven members divided into three classes, with a majority deemed independent under Nasdaq standards.

• Board leadership is separated, with an independent non-executive chair.

• Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Research & Development.

• Annual board and committee self-assessments are conducted.

• Shareholder communications and director nomination processes are formalized.